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Background: 
Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous system. The 
cause of MS is still unknown, but it is considered to be multifactorial. A combination of clinical 
examination, radiological, and laboratory methods according to the McDonald diagnostic criteria 
confirms the diagnosis with high probability. Management of MS includes disease-modifying drugs that 
show different levels of efficacy. Cladribine is an antimetabolite drug indicated for the treatment of 
highly active relapsing-remitting MS based on clinical or imaging features.  
Case presentation: 
A 45-year-old female patient was diagnosed with MS in 2014. She presented with right-sided optic 
neuritis. Magnetic resonance imaging (MRI) of the brain and orbits revealed multiple supra and 
infratentorial demyelinating lesions and hyperintensity of the right optic nerve. Visual evoked potentials 
demonstrated conduction block on the right side. Cerebrospinal fluid analysis displayed intrathecal 
synthesis. Treatment with dimethyl fumarate was introduced. On the control MRI in June 2018, there 
was a newly formed lesion with post-contrast imbibition at the C3-C4 segment of the spinal cord. Due 
to the exacerbation of the disease, cladribine therapy was introduced in 2018 with a good clinical 
response. MRI from August 2019 showed no new lesions. The patient received the second cycle of 
cladribine in August and September 2019. The last control MRI from May 2020 showed one new 
juxtacortical non-active lesion at the tip of the right temporal lobe without clinical correlation. 
Conclusion:  
As a purine analogue with chloride substituent, cladribine targets lymphocytes and leads to their 
apoptosis. The criteria for initiating therapy is lymphocyte count in the reference interval. 
Contraindications are HIV infection, active chronic infection, active malignant disease, and creatinine 
clearance <60mL/min. Laboratory, imaging and clinical follow up are mandatory in monitoring 
therapeutic response and possible side-effects of the treatment. 
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